专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

51. 发明公开

EP1232252A4 REVERSIBLY INACTIVATED ACIDIFIED PLASMIN 有权转让
标题翻译：反应不确定性ANGESÄUERTESPLASMIN
公开(公告)号：EP1232252A4
公开(公告)日：2004-10-20
申请号：EP00990910
申请日：2000-11-13
申请人： BAYER HEALTHCARE LLC
发明人： ZIMMERMAN THOMAS P , NOVOKHATNY VALERY , JIANG SHAN , COLANDENE JAMES
IPC分类号： C12N9/99 , A61B17/00 , A61K9/19 , A61K38/00 , A61K38/48 , A61K47/02 , A61K47/10 , A61K47/12 , A61K47/18 , A61K47/22 , A61K47/26 , A61K47/36 , A61K47/42 , A61M25/00 , A61P7/02 , A61P9/10 , C12N9/68 , C12N9/96 , C12N9/48 , A61K9/50 , C12N9/72 , C12N9/76
CPC分类号： C12N9/6435 , A61K38/4833 , A61K38/484 , A61K45/06 , A61K47/02 , A61K47/12 , A61K47/183 , A61K47/26 , C12N9/96 , C12N9/99 , C12Y304/21007
摘要： The present invention provides a fibrinolytic composition useful as a therapeutic for administration to a patient having a thrombotic occlusion. In one aspect of the present invention, the fibrinolytic composition comprises a reversibly inactivated acidified serine protease substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent. In another aspect of the invention, the fibrinolytic composition of the present invention comprises a reversibly inactivated acidified plasmin substantially free of a plasminogen activator, a low buffering capacity buffer, and optionally, a stabilizing agent.
摘要翻译：本发明提供一种纤维蛋白溶解组合物，其可用作用于给予具有血栓闭塞的患者的治疗剂。在本发明的一个方面，纤维蛋白溶解组合物包含可逆地灭活的酸性丝氨酸蛋白酶，其基本上不含纤溶酶原激活剂，低缓冲能力的缓冲液和任选的稳定剂。在本发明的另一方面，本发明的纤维蛋白溶解组合物包含基本上不含纤溶酶原激活剂，低缓冲能力缓冲液和任选的稳定剂的可逆灭活的酸化纤溶酶。

52. 发明公开

EP1390062A2 MODULATORS OF ELASTASE INHIBITOR SECRETION 审中-公开
标题翻译：弹性蛋白酶抑制剂分泌的调节剂
公开(公告)号：EP1390062A2
公开(公告)日：2004-02-25
申请号：EP02731637.1
申请日：2002-05-02
申请人： CENTER FOR BLOOD RESEARCH, INC.
发明人： REMOLD-O'DONNELL, Eileen
IPC分类号： A61K38/48 , C12N9/66 , C12N9/76 , C12N9/50 , C12N5/00 , C12N5/08
CPC分类号： A61K38/482 , A61K38/4826 , A61K38/486 , A61K2300/00
摘要： The invention provides methods and agents for stimulating the release of monocyte/neutrophil elastase inhibitor from a cell, and the invention also provides methods for identifying agents that stimulate monocyte/neutrophil elastase inhibitor release from a cell. The methods and agents disclosed are useful in the management of inflammatory conditions and diseases.

53. 发明公开

EP1343873A1 A METHOD FOR THE PURIFICATION OF CHYMOSIN 有权
标题翻译：程序提纯凝乳酶
公开(公告)号：EP1343873A1
公开(公告)日：2003-09-17
申请号：EP01271435.8
申请日：2001-12-19
申请人： DSM IP Assets B.V. , APBiotech AB
发明人： FÄHRENMARK, Johan , LAGERLUND, Inger , MORENWEISER, Robert , CAUSSETTE, Mylene , PIRON, Eric
IPC分类号： C12N9/00 , C12N9/50 , C12N9/64 , C12N9/76
CPC分类号： C12N9/6481
摘要： A method for purifying chymosin comprising the steps of: providing an aqueous liquid sample containing chymosin and a separation medium comprising a base matrix and a plurality of firmly attached ligands that are capable of binding to chymosin; contacting the matrix with the sample under conditions permitting binding of chymosin to the matrix; and desorbing chymosin from the matrix. The characterizing feature is that the matrix is hydrophilic and that the ligands in the plurality of ligands are hydrocarbon groups in which all carbon atoms are sp3-hybridised, possibly with an ether oxygen or a thioether sulphur inserted between two carbon atoms at one or more positions in at least one of the hydrocarbon groups, and possibly a hydroxy group replacing a hydrogen atom at one or more positions in at least one of the hydrocarbon groups. The invention also covers that a matrix with or without the ligands and having a hydrophilic/hydrophobic balance that in the test given in the experimental part gives a retention time (r) for α-chymotrypsinogen which is within the interval r¿standard? ± 50% where r¿standard? is the retention time for α-chymotrypsinogen on variant B of n-butyl-OCH2CH(OH)CH2-Sepharose Fast Flow.

54. 发明公开

EP0858504A4 DIAGNOSTICS AND TREATMENTS OF PERIODONTAL DISEASE 失效
标题翻译：诊断和治疗疾病牙周
公开(公告)号：EP0858504A4
公开(公告)日：2002-12-04
申请号：EP96934198
申请日：1996-10-30
申请人： UNIV MELBOURNE , VICTORIAN DAIRY IND
发明人： REYNOLDS ERIC CHARLES , BHOGAL PETER SINGH , SLAKESKI NADA
IPC分类号： C12N9/76 , A61K31/00 , A61K38/00 , A61K39/02 , A61K39/395 , A61P1/00 , A61P1/02 , A61P37/00 , A61P37/04 , C07K2/00 , C07K16/12 , C12N9/52 , A61K39/40
CPC分类号： C12N9/52 , A61K38/00

55. 发明公开

EP1043406A4 ANALYSIS OF PREDISPOSITION BASED ON HUMAN AIRWAY TRIPSIN PROTEASE GENE POLYMORPHISM 有权
标题翻译：基于该人呼吸道胰蛋白酶蛋白酶的基因多态性的易感性
公开(公告)号：EP1043406A4
公开(公告)日：2002-11-04
申请号：EP98961367
申请日：1998-12-16
申请人： TEIJIN LTD
发明人： EGUCHI HIROSHI , YAMAOKA KAZUYOSHI , MASUDA KENICHI , YASUOKA SUSUMU
IPC分类号： C12N9/76 , C12Q1/68 , C12N15/11 , C12Q1/44
CPC分类号： C12N9/6427 , C12Q1/6883 , C12Q2600/156 , C12Q2600/172
摘要： A method for predicting the predisposition of individuals to specific diseases, for example, respiratory diseases such as chronic obstructive pulmonary disease, sinobronchial syndrome, pulmonary emphysema, diffuse bronchiolitis and bronchiectasis, therapeutic effects on patients or the prognosis following the treatments, based on human airway tripsin protease gene polymorphism.

56. 发明公开

EP1250442A2 METHOD FOR THE MANUFACTURE OF RECOMBINANT TRYPSIN 有权
标题翻译：工艺生产重组胰蛋白酶
公开(公告)号：EP1250442A2
公开(公告)日：2002-10-23
申请号：EP01911524.5
申请日：2001-01-24
申请人： Polymun ScientificImmunbiologische Forschung GmbH
发明人： MATTANOVICH, Diethard , KATINGER, Hermann , HOHENBLUM, Hubertus , NASCHBERGER, Stefan , WEIK, Robert
IPC分类号： C12N15/57 , C12N9/76 , C12M1/00
CPC分类号： C12N9/6427
摘要： The present invention relates to a method for the manufacture andpurification of recombinant trypsinogen and trypsin in E. coli and yeast, using high yield expression vectors with and without secretion leader sequences. The invention further relates to an improved method and apparatus for carrying out protein refolding specifically useful for processing trypsinogen that has accumulated intracellularly in the form of inclusion bodies.

57. 发明公开

EP1141263A1 PRODUCTION OF SOLUBLE RECOMBINANT TRYPSINOGEN ANALOGS 审中-公开
标题翻译：生产可溶性重组TRYPSINANALOGEN的
公开(公告)号：EP1141263A1
公开(公告)日：2001-10-10
申请号：EP99951445.8
申请日：1999-09-15
申请人： ELI LILLY AND COMPANY , UNIVERSITE LOUIS PASTEUR
发明人： HANQUIER, Jose, Michael , HERSHBERGER, Charles, Lee , DESPLANCQ, Dominique , LARSON, Jeffery, Lynn , ROSTECK, Paul, Robert, Jr.
IPC分类号： C12N9/76 , C12N15/11 , C12N15/57 , C12N15/62 , C12N15/79 , C12N15/81
CPC分类号： C12N9/6427
摘要： The present invention relates to recombinantly produced trypsin and trypsinogen analogs, including nucleic acids which encode trypsin and trypsinogen analogs. The trypsinogen analogs of the present invention contain modifications of the trypsinogen leader sequence such that the trypsinogen cannot be cleaved by trypsin or trypsin-like enzymes. The present invention also includes processes for producing recombinant trypsinogen analogs which can subsequently be activated.

58. 发明公开

EP1012307A1 AUTOKATALYTISCH AKTIVIERBARE ZYMOGENE VORSTUFEN VON PROTEASEN UND DEREN VERWENDUNG 有权
标题翻译：蛋白酶及其使用活性炭催化前体酶原
公开(公告)号：EP1012307A1
公开(公告)日：2000-06-28
申请号：EP98945214.9
申请日：1998-08-12
申请人： Roche Diagnostics GmbH
发明人： KOPETZKI, Erhard , HOPFNER, Karl-Peter , BODE, Wolfram , HUBER, Robert
IPC分类号： C12N15/57 , C12N9/50 , C12N9/64 , C12N9/76 , C12P21/06
CPC分类号： C12N9/647 , C12N9/50 , C12N9/6427 , C12N9/6432 , C12Y304/21006
摘要： A process for the recombinant production of a protease is characterised by (a) transformation of a host cell with a recombinant nucleic acid which codes for a zymogenic protease precursor containing an autocatalytic cleavage site which does not occur naturally, this cleavage site being recognised by the active form of said protease, cleaving the zymogenic precursor into the active protease; (b) cultivation of the host cell such that the zymogenic protease precursor is created in the host cell in the form of inclusion bodies; (c) isolation and naturalisation of the inclusion bodies in such conditions that the protease part of the zymogenic precursor is produced with its natural conformation; and (d) autocatalytic cleavage of the naturalised zymogenic precursor to produce the active protease. This process is suitable to produce recombinant proteases in a simple manner and with high yields.

59. 发明公开

EP0926235A2 Method of stabilizing trypsin 审中-公开
标题翻译： Verfahren zur Stabilisierung von胰蛋白酶
公开(公告)号：EP0926235A2
公开(公告)日：1999-06-30
申请号：EP98309920.1
申请日：1998-12-03
申请人： Kyoto Daiichi Kagaku Co., Ltd.
发明人： Yonehara, Satoshi
IPC分类号： C12N9/96 , C12N9/76 , C12Q1/37
CPC分类号： C12N9/6427 , C12N9/96
摘要： The present invention provides a method for stabilizing trypsin, in which enzyme reaction of trypsin can be generated in a two-solution system, degradation of trypsin and its substrate can be prevented, and enzymatic activity of trypsin is improved compared to conventional methods, and which can be sufficiently applied to an automatic analyzer. An enzyme solution is prepared by dissolving trypsin in a buffer solution having a pH at which enzymatic activity of trypsin is active and containing calcium and/or manganese ions. It is preferable that the total concentration of the calcium ions and the manganese ions in the buffer solution is in the range of 3 to 10 mmol/l. It is also preferable that the concentration of the buffer solution is at least 10 mmol/l, and that the pKa of the buffer solution is higher than the pH of the buffer solution.
摘要翻译：本发明提供了一种稳定胰蛋白酶的方法，其中可以在双溶液体系中产生胰蛋白酶的酶反应，可以防止胰蛋白酶及其底物的降解，与常规方法相比，胰蛋白酶的酶活性提高，可以充分地应用于自动分析仪。通过将胰蛋白酶溶解在具有胰蛋白酶的酶活性并含有钙离子和/或锰离子的pH的缓冲溶液中来制备酶溶液。缓冲溶液中的钙离子和锰离子的总浓度优选为3〜10mmol / l。还优选缓冲溶液的浓度为至少10mmol / l，缓冲溶液的pKa高于缓冲溶液的pH。

60. 发明授权

EP0565512B1 Verfahren zur Aktivierung von Blutgerinnungsfaktoren 失效
标题翻译：一种用于血液凝固因子的活化过程
公开(公告)号：EP0565512B1
公开(公告)日：1998-12-16
申请号：EP93890047.9
申请日：1993-03-19
申请人： IMMUNO Aktiengesellschaft
发明人： Linnau, Yendra, Dr.
IPC分类号： C12N9/76 , C12N9/74 , C12N11/00
CPC分类号： C12N9/6429 , C12N9/6427 , C12N9/647 , C12Y304/21005

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式